<DOC>
	<DOCNO>NCT01155479</DOCNO>
	<brief_summary>This one year , 2-part study determine efficacy safety preladenant , adenosine type 2a ( A2a ) receptor antagonist . The purpose Part 1 ( first 26 week ) determine preladenant effective treatment early Parkinson 's Disease . The purpose Part 2 ( second 26 week ) determine preladenant safe well tolerate . The primary efficacy hypothesis least 10 mg twice daily dose preladenant superior placebo measure change Baseline Week 26 sum Unified Parkinson 's Disease Rating Scale ( UPDRS ) Parts 2 3 score ( UPDRS2+3 ) .</brief_summary>
	<brief_title>A Placebo- Active-Controlled Study Preladenant Early Parkinson 's Disease ( PD ) ( P05664 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Has diagnosis idiopathic PD &lt; 5 year . If receive amantadine and/or anticholinergic , must stable regimen treatment least 5 week immediately Screening . ( Note : Participants take medication PD permit enroll trial . ) Must UPDRS Part 3 score ≥10 , Hoehn Yahr Stage ≤3 , ≥30 ≤85 year age , result Screening clinical laboratory test draw within 5 week prior randomization , clinically acceptable investigator , within parameter specify exclusion . If sexually active plan sexually active , must agree use highly effective method birth control participant study 2 week last dose study drug . A male participant must also donate sperm trial within 2 week last dose study drug . Must form druginduced atypical Parkinsonism , cognitive impairment ( ie , Montreal Cognitive Assessment [ MoCA ] score &lt; 22 ) , bipolar disorder , untreated major depressive disorder , schizophrenia , psychotic disorder ; history exposure know neurotoxin , neurological feature consistent diagnosis PD assess investigator . Must surgery PD . Must history repeat stroke stepwise progression Parkinsonism head injury , stroke within 6 month screen ; poorly control diabetes ; abnormal renal function ; severe ongoing unstable medical condition . Must fail show therapeutic response diagnostic levodopa ( L dopa ) challenge do large test dose ( &gt; 500 mg ) L dopa ( malabsorption exclude ) , fail respond adequate previous treatment dopaminergic therapy . Must treat L dopa dopamine agonists 30 day . A participant treat Ldopa dopamine agonist &lt; 30 day allow enter study . These participant must stop take dopaminergic medication 30 day prior Randomization . Must imminent risk selfharm harm others . Must elevate blood pressure ( BP ) ( systolic BP ≥150 mm Hg diastolic BP ≥95 mm Hg ) adequately control antihypertensive medication , demonstrate 2 BP measurement meet acceptable BP criterion consecutive schedule unscheduled visit Screening Randomization ( 56 week period ) , one must Randomization visit . Must clinically significant cardiovascular event procedure 6 month prior Randomization , include , limited , myocardial infarction , angioplasty , unstable angina , heart failure ; participant must heart failure stag New York Heart Association Class III IV . Must alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) ≥ 3 x upper limit normal ( ULN ) total bilirubin ( T BIL ) ≥ 1.5 x ULN . Must active serologicallyconfirmed hepatic dysfunction ( defined viral infection [ Hepatitis B , C , E ; EpsteinBarr virus ( EBV ) ] ; cytomegalovirus [ CMV ] history diagnosis drug alcoholinduced hepatic toxicity frank hepatitis , history diagnosis drug alcoholinduced hepatic toxicity frank hepatitis . ) Must history within past 5 year primary recurrent malignant disease exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ prostate cancer normal prostatespecific antigen ( PSA ) post resection . Must receive certain prespecified medication ingest high tyraminecontaining age cheese ( eg , Stilton ) prespecified time window trial , trial , 2 week trial . Must average daily consumption three 4 ounce glass ( 118 mL ) wine equivalent . Must severe ongoing unstable medical condition ( eg , form clinically significant cardiac disease , symptomatic orthostatic hypotension , seizure , alcohol/drug dependence . ) Must allergy/sensitivity investigational product ( ) its/their excipients . Must breastfeeding , consider breastfeeding , pregnant intend become pregnant . Must use preladenant ever , investigational drug within 90 day immediately screen .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>